Coronavirus Disease 2019 Related Clinical Studies: A Cross-Sectional Analysis

Overview

Journal Front Pharmacol

Date 2020 Sep 28

PMID 32982751

Citations 3

Authors

Lin-Lu Ma

Xuan Yin

Bing-Hui Li

Jia-Yu Yang

Ying-Hui Jin

Di Huang

Tong Deng

Yun-Yun Wang

Xue-Qun Ren

Jianguang Ji

Xian-Tao Zeng

Affiliations

Soon will be listed here.

Abstract

Objective: The quality and rationality of many recently registered clinical studies related to coronavirus disease 2019 (COVID-19) needs to be assessed. Hence, this study aims to evaluate the current status of COVID-19 related registered clinical trial.

Methods: We did an electronic search of COVID-19 related clinical studies registered between December 1, 2019 and February 21, 2020 (updated to May 28, 2020) from the , and collected registration information, study details, recruitment status, characteristics of the subjects, and relevant information about the trial implementation process.

Results: A total of 1,706 studies were included 10.0% of which (n=171) were from France, 943 (55.3%) used an interventional design, and 600 (35.2%) used an observational design. Most of studies (73.6%) aimed to recruit fewer than 500 people. Interferon was the main prevention program, and antiviral drugs were the main treatment program. Hydroxychloroquine and chloroquine (230/943, 24.4%) were widely studied. Some registered clinical trials are incomplete in content, and 37.4% of the 1,706 studies may have had insufficient sample size.

Conclusion: The quality of COVID-19 related studies needs to be improved by strengthening the registration process and improving the quality of clinical study protocols so that these clinical studies can provide high-quality clinical evidence related to COVID-19.

Citing Articles

Antimicrobial peptides: A promising tool to combat multidrug resistance in SARS CoV2 era.

Saini J, Kaur P, Malik N, Lakhawat S, Sharma P Microbiol Res. 2022; 265:127206.

PMID: 36162150 PMC: 9491010. DOI: 10.1016/j.micres.2022.127206.

How the clinical research community responded to the COVID-19 pandemic: an analysis of the COVID-19 clinical studies in ClinicalTrials.gov.

He Z, Erdengasileng A, Luo X, Xing A, Charness N, Bian J JAMIA Open. 2021; 4(2):ooab032.

PMID: 34056559 PMC: 8083215. DOI: 10.1093/jamiaopen/ooab032.

How the clinical research community responded to the COVID-19 pandemic: An analysis of the COVID-19 clinical studies in ClinicalTrials.gov.

He Z, Erdengasileng A, Luo X, Xing A, Charness N, Bian J medRxiv. 2020; .

PMID: 32995807 PMC: 7523146. DOI: 10.1101/2020.09.16.20195552.

References

Norris S, Louis H, Sawin V, Porgo T, Lau Y, Wang Q . An evaluation of WHO emergency guidelines for Zika virus disease. J Evid Based Med. 2019; 12(3):218-224. PMC: 6771472. DOI: 10.1111/jebm.12347. View

Yu F, Du L, Ojcius D, Pan C, Jiang S . Measures for diagnosing and treating infections by a novel coronavirus responsible for a pneumonia outbreak originating in Wuhan, China. Microbes Infect. 2020; 22(2):74-79. PMC: 7102556. DOI: 10.1016/j.micinf.2020.01.003. View

Li Z, Yi Y, Luo X, Xiong N, Liu Y, Li S . Development and clinical application of a rapid IgM-IgG combined antibody test for SARS-CoV-2 infection diagnosis. J Med Virol. 2020; 92(9):1518-1524. PMC: 7228300. DOI: 10.1002/jmv.25727. View

Bhatt D, Mehta C . Adaptive Designs for Clinical Trials. N Engl J Med. 2016; 375(1):65-74. DOI: 10.1056/NEJMra1510061. View

Goldacre B . The WHO joint statement from funders on trials transparency. BMJ. 2017; 357:j2816. DOI: 10.1136/bmj.j2816. View

Liu Y, Yang Y, Zhang C, Huang F, Wang F, Yuan J . Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. Sci China Life Sci. 2020; 63(3):364-374. PMC: 7088566. DOI: 10.1007/s11427-020-1643-8. View

Haagmans B, Kuiken T, Martina B, Fouchier R, Rimmelzwaan G, van Amerongen G . Pegylated interferon-alpha protects type 1 pneumocytes against SARS coronavirus infection in macaques. Nat Med. 2004; 10(3):290-3. PMC: 7095986. DOI: 10.1038/nm1001. View

Mehta H, Ehrhardt S, Moore T, Segal J, Alexander G . Characteristics of registered clinical trials assessing treatments for COVID-19: a cross-sectional analysis. BMJ Open. 2020; 10(6):e039978. PMC: 7286283. DOI: 10.1136/bmjopen-2020-039978. View

Tian X, Li C, Huang A, Xia S, Lu S, Shi Z . Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody. Emerg Microbes Infect. 2020; 9(1):382-385. PMC: 7048180. DOI: 10.1080/22221751.2020.1729069. View

10.

Zhou P, Yang X, Wang X, Hu B, Zhang L, Zhang W . A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020; 579(7798):270-273. PMC: 7095418. DOI: 10.1038/s41586-020-2012-7. View

11.

Zhou S, Lukula S, Chiossone C, Nims R, Suchmann D, Ijaz M . Assessment of a respiratory face mask for capturing air pollutants and pathogens including human influenza and rhinoviruses. J Thorac Dis. 2018; 10(3):2059-2069. PMC: 5906272. DOI: 10.21037/jtd.2018.03.103. View

12.

Horby P, Lim W, Emberson J, Mafham M, Bell J, Linsell L . Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med. 2020; 384(8):693-704. PMC: 7383595. DOI: 10.1056/NEJMoa2021436. View

13.

Tang W, Cao Z, Han M, Wang Z, Chen J, Sun W . Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. BMJ. 2020; 369:m1849. PMC: 7221473. DOI: 10.1136/bmj.m1849. View

14.

Lu R, Zhao X, Li J, Niu P, Yang B, Wu H . Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020; 395(10224):565-574. PMC: 7159086. DOI: 10.1016/S0140-6736(20)30251-8. View

15.

Zhou D, Dai S, Tong Q . COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression. J Antimicrob Chemother. 2020; 75(7):1667-1670. PMC: 7184499. DOI: 10.1093/jac/dkaa114. View

16.

Hou Y, Wu J, Tan C, Chen Y, Guo R, Luo Y . Sex-based differences in the prevalence of acute mountain sickness: a meta-analysis. Mil Med Res. 2019; 6(1):38. PMC: 6900850. DOI: 10.1186/s40779-019-0228-3. View

17.

Ruberg S, Akacha M . Considerations for Evaluating Treatment Effects From Randomized Clinical Trials. Clin Pharmacol Ther. 2017; 102(6):917-923. DOI: 10.1002/cpt.869. View

18.

Schulz K, Grimes D . Blinding in randomised trials: hiding who got what. Lancet. 2002; 359(9307):696-700. DOI: 10.1016/S0140-6736(02)07816-9. View

19.

Ludvigsson J . Systematic review of COVID-19 in children shows milder cases and a better prognosis than adults. Acta Paediatr. 2020; 109(6):1088-1095. PMC: 7228328. DOI: 10.1111/apa.15270. View

20.

Sarma P, Kaur H, Kumar H, Mahendru D, Avti P, Bhattacharyya A . Virological and clinical cure in COVID-19 patients treated with hydroxychloroquine: A systematic review and meta-analysis. J Med Virol. 2020; 92(7):776-785. PMC: 7262144. DOI: 10.1002/jmv.25898. View